Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M
Department of Surgical Sciences, Section of Anaesthesiology and Intensive Care Medicine, Karolinska Institute, Stockholm, Sweden.
Crit Care Med. 2001 Nov;29(11):2185-93. doi: 10.1097/00003246-200111000-00022.
Levosimendan is a novel inodilator that improves cardiac contractility by sensitizing troponin C to calcium. This drug has proved to be effective in treating advanced congestive heart failure but has not been evaluated in septic settings. The purpose of the present study was to study the effects of this drug in a porcine model of endotoxemia.
Prospective experimental study.
Fourteen landrace pigs.
All animals were anesthetized and catheterized for measurement of central and pulmonary hemodynamics. Ultrasonic flow probes were placed around the renal artery and portal vein to measure blood flow. A tonometer was placed in the ileum to measure mucosal pH. Levosimendan was given to six animals as a bolus (200 microg x kg(-1)) followed by a continuous infusion (200 microg x kg(-1) x hr(-1)). Thirty minutes after onset of levosimendan treatment, all animals received endotoxin (20 microg x kg(-1) x hr(-1) for 3 hrs).
At baseline, levosimendan induced a systemic vasodilation with a reduction in blood pressure and an increase in heart rate. A tendency to an increase in cardiac index did not reach statistical significance (p =.055). Cardiac index and systemic oxygen delivery were markedly improved in the levosimendan group during endotoxemia. Systemic vascular resistance and blood pressure were reduced in the levosimendan group. The latter parameter, however, was only different from the control group during the initial phase of endotoxin shock but not at the late, most pronounced phase of shock. Levosimendan also efficiently attenuated endotoxin-induced pulmonary hypertension. Portal venous blood flow and gut oxygen delivery were improved, but no concomitant reduction in endotoxin-induced intestinal mucosal acidosis was observed. Renal blood flow was unaffected, as was the endotoxin-induced increase in plasma endothelin-1-like immunoreactivity. These findings support previous reports of calcium desensitization as a potential component in septic myocardial depression. Furthermore, the vasodilatory properties of this drug were well tolerated in the current model of hypodynamic endotoxin shock, and they may have contributed to improved regional blood flow as seen in the gut as well as improved systemic perfusion by means of reduced biventricular afterload.
Pretreatment with levosimendan in pigs subjected to endotoxin shock improved cardiac output and systemic and gut oxygen delivery. In addition, pulmonary hypertension largely was attenuated without any adverse effects on gas exchange. These results are promising in several aspects, but the role of levosimendan in the treating circulatory failure in sepsis remains to be established.
左西孟旦是一种新型的强心剂,通过使肌钙蛋白C对钙敏感来增强心脏收缩力。该药物已被证明对治疗晚期充血性心力衰竭有效,但尚未在脓毒症环境中进行评估。本研究的目的是研究该药物在内毒素血症猪模型中的作用。
前瞻性实验研究。
14头长白猪。
所有动物均接受麻醉并插入导管以测量中心和肺血流动力学。在肾动脉和门静脉周围放置超声流量探头以测量血流量。在回肠放置一个张力计以测量黏膜pH值。给6只动物静脉推注左西孟旦(200μg·kg⁻¹),随后持续输注(200μg·kg⁻¹·h⁻¹)。左西孟旦治疗开始30分钟后,所有动物接受内毒素(20μg·kg⁻¹·h⁻¹,持续3小时)。
在基线时,左西孟旦引起全身血管舒张,血压降低,心率增加。心脏指数有增加的趋势,但未达到统计学意义(p = 0.055)。在内毒素血症期间,左西孟旦组的心脏指数和全身氧输送显著改善。左西孟旦组的全身血管阻力和血压降低。然而,后一参数仅在内毒素休克的初始阶段与对照组不同,而在休克的晚期、最明显阶段则无差异。左西孟旦还有效减轻了内毒素诱导的肺动脉高压。门静脉血流量和肠道氧输送得到改善,但未观察到内毒素诱导的肠黏膜酸中毒相应减轻。肾血流量未受影响,内毒素诱导的血浆内皮素-1样免疫反应性增加也未受影响。这些发现支持了先前关于钙脱敏作为脓毒症性心肌抑制潜在成分的报道。此外,在当前的低动力性内毒素休克模型中,该药物的血管舒张特性耐受性良好,并且它们可能有助于改善肠道等部位的局部血流以及通过降低双心室后负荷改善全身灌注。
在内毒素休克猪中,左西孟旦预处理可改善心输出量以及全身和肠道氧输送。此外,肺动脉高压在很大程度上得到减轻,且对气体交换无任何不良影响。这些结果在几个方面都很有前景,但左西孟旦在治疗脓毒症循环衰竭中的作用仍有待确定。